Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Bladder01:23

Urinary Bladder

2.0K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
2.0K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

65
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
65
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

419
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
419
Urodynamic Studies: Uroflowmetry01:19

Urodynamic Studies: Uroflowmetry

1.2K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
1.2K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

383
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
383
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

287
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
287

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Periprocedural anti-thrombotic therapy and priapism recurrence after surgical shunting: a propensity-matched analysis.

The journal of sexual medicine·2026
Same author

Predicting major ischemic priapism: a novel dynamic nomogram based on recurrent ischemic priapism risk factors.

The journal of sexual medicine·2026
Same author

Changes in sexual quality of life in patients with stress urinary incontinence treated with an artificial urinary sphincter; analysis of the artificial urinary sphincter clinical outcomes trial (AUSCO).

The journal of sexual medicine·2026
Same author

Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.

JAMA internal medicine·2026
Same author

Safety and tolerability of a novel implantable neurostimulator to improve erectile function: a pilot study in patients with spinal cord injury.

The journal of sexual medicine·2026
Same author

Massive hemorrhage and cardiac arrest due to ureteroarterial fistula following nephroureteral stent removal: A case report.

Urology case reports·2026

Related Experiment Video

Updated: Oct 30, 2025

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.6K

Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study.

Serkan Karakus1, Biljana Musicki1, Arthur L Burnett2

  • 1The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

International Journal of Impotence Research
|July 3, 2021
PubMed
Summary
This summary is machine-generated.

Mirabegron showed potential in improving erectile function (EF) and overactive bladder (OAB) symptoms in men with both conditions. While not a universal solution, it offered benefits for some without serious side effects.

More Related Videos

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

405
Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

23.3K

Related Experiment Videos

Last Updated: Oct 30, 2025

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.6K
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

405
Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

23.3K

Area of Science:

  • Urology
  • Pharmacology
  • Men's Health

Background:

  • Phosphodiesterase type 5 inhibitors (PDE5i) are the primary oral treatment for erectile dysfunction (ED) in the US.
  • Alternative ED treatments are needed for patients unresponsive or contraindicated to PDE5i.
  • Targeting pathways beyond the NO-cGMP pathway may offer new therapeutic options for ED.

Purpose of the Study:

  • To evaluate Mirabegron's efficacy in improving erectile function (EF) in men with concurrent overactive bladder (OAB) and mild to moderate ED.
  • To assess the impact of Mirabegron on OAB symptoms and health-related quality of life (HRQL).
  • To determine the safety and tolerability of Mirabegron in this patient population.

Main Methods:

  • A 12-week study involving 20 male subjects (40-70 years) with OAB and mild to moderate ED.
  • Participants received Mirabegron therapy and completed the International Index of Erectile Function (IIEF) and Overactive Bladder questionnaire (OAB-q) at regular intervals.
  • Primary endpoint: increase in IIEF-5 score by 4 units; Secondary endpoint: decrease in OAB-q symptom severity score by 10 units.

Main Results:

  • Mirabegron improved IIEF-5 scores by 4 points or more in 38.4% of participants.
  • Significant improvements were noted in intercourse satisfaction (week 8) and OAB symptoms (OAB-q short form and total HRQL scores).
  • No serious adverse events were reported; residual bladder volumes remained unaffected.

Conclusions:

  • Mirabegron demonstrated potential in improving erectile function and OAB symptoms in some men with concurrent conditions.
  • The treatment was well-tolerated, with no serious adverse events observed.
  • Further research may explore Mirabegron's role as an alternative or adjunctive therapy for ED and OAB.